Skip to main content
NTHI
NASDAQ Life Sciences

NEONC Technologies Agrees to Sell $5M in Highly Dilutive Convertible Preferred Stock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$4.88
Mkt Cap
$117.059M
52W Low
$3.2
52W High
$12.99
52W Position info
52% above low
Off High info
62% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

NTHI sits 52% above its 52-week low of $3.2 on light trading volume (0.4× avg).

Summary

NEONC Technologies is raising up to $5 million through a private placement of Series A Convertible Preferred Stock, with terms that could lead to substantial dilution for common shareholders if the company cannot redeem the preferred shares.


Key Events · Financing and Capital Events · NTHI

  • New Convertible Preferred Stock Offering

    The company has entered into an agreement to sell up to $5 million in Series A Convertible Preferred Stock in a private placement, with a purchase price of $833.34 per share and a stated value of $1,000 per share. The closing is subject to customary conditions.

  • Highly Dilutive Conversion Terms

    If not redeemed by the company, the preferred stock becomes convertible into common stock at 80% of the lowest closing price over the five trading days prior to conversion, subject to a $1.00 floor. This mechanism is highly favorable to investors and potentially very dilutive to common shareholders.

  • Company Redemption Option

    NEONC Technologies has the option to redeem the preferred stock at its stated value within four months, with two one-month extensions, potentially avoiding conversion if financial conditions improve.

  • Adds to Existing Dilution Risk

    This financing follows recent dilutive events, including a $300 million shelf registration, a $75 million At-The-Market offering, and a proposed amendment to the equity incentive plan, further increasing potential shareholder dilution.


Analysis · NTHI · Life Sciences

NEONC Technologies has entered into an agreement to sell up to $5 million in Series A Convertible Preferred Stock. While this provides much-needed capital for a company facing a 'going concern' warning, the terms are highly dilutive for common shareholders. The preferred stock can convert at 80% of the lowest closing price over five trading days, with a $1.00 floor, if the company fails to redeem it. This structure indicates the company's urgent need for funds and the significant concessions made to secure financing, adding to the existing dilution from prior offerings and a proposed equity plan amendment.

At the time of this filing, NTHI was trading at $4.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $117.1M. The 52-week trading range was $3.20 to $12.99. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NTHI - Latest Insights

NTHI
Jul 15, 2026, 9:23 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $3.95
Real-time Price: $3.52 info
Change: -$0.430 (-11%) info
Market Cap: $91.28M info
NTHI
Jul 15, 2026, 9:15 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.72
Real-time Price: $3.52 info
Change: -$0.200 (-5%) info
Market Cap: $91.28M info
NTHI
Jul 02, 2026, 5:11 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.42
Real-time Price: $3.52 info
Change: -$0.900 (-20%) info
Market Cap: $91.28M info
NTHI
Jun 23, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.88
Real-time Price: $3.52 info
Change: -$1.36 (-28%) info
Market Cap: $91.28M info
NTHI
Jun 23, 2026, 5:00 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $4.88
Real-time Price: $3.52 info
Change: -$1.36 (-28%) info
Market Cap: $91.28M info